Blood and blood components imported from third countries, including those used as starting material/raw material for the manufacture of medicinal products derived from human blood and human plasma, should meet the quality and safety requirements set out in this Directive.
Recital 4, Directive (EU) 2004/33
In forcesince 22 Mar 2004cited 1×
Opinion of Advocate General Mengozzi delivered on 17 July 2014. Geoffrey Léger v Ministre des Affaires sociales, de la Santé et des Droits dDecision
Its adoption is part of a context in which the Member States had previously experienced failings in their systems for monitoring and securing the transfusion chain. Consequently, the supranational authorities took up the matter, at the …
17 Jul 2014 · 62013CC0528